
Tirzepatide
A once-weekly injectable that targets areas in the brain that regulate hunger, leading to reduced food cravings as well as helping you feel fuller longer after eating.
Weight Management
Approved for adults with obesity (BMI of 30 kg/m² or greater) or those who are overweight (BMI of 27 kg/m² or greater) with at least one weight-related condition, such as high blood pressure or high cholesterol. It is also used to treat moderate to severe obstructive sleep apnea (OSA) in patients with obesity.
Mechanism
Tirzepatide activates GIP and GLP-1 receptors in the body, including those in the brain that regulate appetite, leading to reduced food intake and lower blood glucose levels.
Administration
It is administered as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm.
Dosage
The typical starting dose is 2.5 mg once weekly, with the dose gradually increased by a healthcare provider every four weeks based on patient response, up to a maximum of 15 mg once weekly.
Effectiveness
Clinical trials have shown significant reductions in both HbA1c and body weight, with some participants losing up to 20% of their initial body weight.
WHAT OUR PATIENTS ARE SAYING